Litigation Details for INTRA-CELLULAR THERAPIES, INC. v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2024)

INTRA-CELLULAR THERAPIES, INC. v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2024)

Docket		Date Filed	2024-03-28
Court	District Court, D. New Jersey	Date Terminated	2024-08-05
Cause	35:145 Patent Infringement	Assigned To	Jennifer Choe-Groves
Jury Demand	None	Referred To	Brendan Day
Patents	10,695,345; 11,052,084; 11,690,842; 11,753,419; 11,806,348
Link to Docket	External link to docket

Details for INTRA-CELLULAR THERAPIES, INC. v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-03-28				External link to document

Last updated: July 29, 2026

ecutive summary
Intra-Cellular Therapies, Inc. v. Zydus Pharmaceuticals (USA) Inc. (Case No. 3:24-cv-04330) is a Hatch-Waxman patent dispute filed in the District of New Jersey in 2024. The record supports a Paragraph IV-style challenge directed to Zydus’s proposed generic of an Intra-Cellular drug. The action creates a near-term injunction risk tied to the specific Orange Book-listed patents and claims asserted. Strategy impact centers on (i) claim construction posture, (ii) whether the asserted patents are formulation, method-of-use, or polymorph/process, and (iii) the likelihood the court narrows or holds the asserted claims invalid/non-infringed.

Intra-Cellular Therapies v. Zydus Pharmaceuticals (USA) Inc. 3:24-cv-04330: litigation summary, asserted patents, and outcome drivers

What is the case status in Intra-Cellular Therapies, Inc. v. Zydus Pharmaceuticals (USA) Inc. (3:24-cv-04330)?

Case No. 3:24-cv-04330 is a federal patent infringement action in the District of New Jersey, filed in 2024. The litigation posture is consistent with a Hatch-Waxman framework tied to an FDA small-molecule “generic” filing and Orange Book exclusivities/patents.

Business implication: the case timing matters for generic launch planning because any court-entered temporary restraining order/preliminary injunction or settlement stay can shift “first-to-market” and launch sequencing by months.

Where is the case filed and who are the parties?

• Plaintiff: Intra-Cellular Therapies, Inc.
• Defendant: Zydus Pharmaceuticals (USA) Inc.
• Court: District of New Jersey
• Case number: 3:24-cv-04330

Which patents does Intra-Cellular assert against Zydus in 3:24-cv-04330?

No complete, claim-level patent-identification details are provided in the input. Without the asserted-patent list (patent numbers and claim snippets), a definitive patent-by-patent infringement/invalidity analysis cannot be produced from the information supplied.

What kind of claims are typically at issue in Intra-Cellular vs. generic defendants for Hatch-Waxman suits?

Intra-Cellular’s patent estates across its portfolio commonly include patent categories that map to generic exposure vectors:

Formulation and composition-of-matter

• Polymorph/crystal form, particle size, salt, solid-state properties
• Fill weight and composition ranges designed to preserve bioavailability and stability
• Coating or excipient selection that impacts dissolution

Generic risk: harder to design around without matching the protected solid-state or process parameters.

Method-of-use and treatment regimen

• Dosing schedules, titration protocols, or specific patient subpopulations
• Combination regimens or therapeutic monitoring steps

Generic risk: “skinny label” and carve-out feasibility depend on the exact label language and the asserted claim scope.

Manufacturing and process patents

• Mixing, granulation, drying, milling parameters
• Conditions that define yield/impurity profiles and downstream bioequivalence

Generic risk: often drives higher-cost process development and tighter control in ANDA manufacturing.

What defenses does Zydus typically raise in Paragraph IV Hatch-Waxman cases?

Common categories include:

Non-infringement

• The accused product does not practice the claim element-by-element
• Bioequivalence strategy avoids the claimed formulation attributes
• Labeling/carve-outs avoid method-of-use elements

Invalidity

• Anticipation or obviousness over prior art
• Indefiniteness, lack of enablement, or written description failures
• Obviousness-type double patenting (OTDP) when applicable

Procedural defenses

• Venue, service, or timing challenges
• Statutory limitations tied to the ANDA approval pathway

How do courts usually evaluate infringement in Hatch-Waxman ANDA cases like 3:24-cv-04330?

Infringement turns on three inputs:

1. Claim construction of the asserted patent terms
2. ANDAs’ proposed product specifications and relevant evidence
3. Labeling for method-of-use disputes

Business takeaway: if claim construction narrows the claim to a specific solid-state attribute or dosing step, infringement can pivot on testing results and formulation documentation.

What is the potential timeline for injunction, discovery, and trial in 3:24-cv-04330?

Without docket events, deadlines, and motions listed in the input, an accurate procedural timeline cannot be produced.

Business implication (general): early claim construction and Daubert posture can determine settlement leverage. If the court sets an aggressive Markman schedule, both sides tend to crystallize invalidity and infringement theories for settlement talks.

What is the settlement and licensing risk profile in this case?

A common Hatch-Waxman settlement pattern is:

• Agreement to delay launch beyond the earliest potential launch date
• Possible license of one or more patents, or covenants not to sue
• Payment or non-monetary consideration structured to avoid breach of antitrust constraints depending on the period and terms

Business implication: settlement likelihood tends to track (i) how close the generic’s formulation is to the asserted formulation/process claims, and (ii) whether the plaintiff’s patents appear strong enough to sustain preliminary injunctive relief.

What does the FDA regulatory posture likely mean for this dispute?

Hatch-Waxman patent litigation is tightly coupled to the ANDA/505(b)(2) pathway.

Orange Book status drives the litigation trigger

Plaintiff’s asserted patents usually appear on the drug’s Orange Book listing tied to the Reference Listed Drug (RLD). Zydus’s filing typically includes a Paragraph IV certification against those patents, triggering suit.

Generic launch exposure depends on:

• Whether patents are found infringed and not invalid
• Whether the court grants an injunction
• Whether an approval is stayed by the statutory framework or settlement

How does this case affect generic entry risk for Zydus?

Even if the court ultimately rules for Zydus, early rulings (Markman, summary judgment, or preliminary injunction outcomes) can:

• Reduce litigation uncertainty
• Change the expected effective date for launch
• Trigger design-around investments or label changes

Business implication: the most immediate “value” of the case is the leverage effect on expected entry timing, not only the final infringement verdict.

How strong is Intra-Cellular’s patent estate in this dispute?

A strength assessment requires the asserted patent numbers, claim sets, and the parties’ invalidity positions. These are not included in the input.

Business implication: the strength of the asserted claims relative to likely prior art and the closeness of the accused formulation to the claim elements are the key drivers. Without that data, a deterministic rating is not possible.

What potential manufacturing or design-around barriers could Zydus face?

Barrier types depend on whether the asserted patents target:

• Solid-state properties: requires new crystallization and analytical confirmation
• Dissolution/bioavailability: may require new formulation development and bridging studies
• Process patents: requires new equipment/process controls and validation batches
• Method-of-use: requires label carve-out strategy and post-marketing compliance

Key case analytics (what to watch)

Given the lack of patent- and docket-level detail in the input, the highest-signal analytics that govern outcomes in cases like 3:24-cv-04330 are:

1. Claim construction direction: whether the court narrows terms toward a single embodiment
2. Evidence of practice: whether Zydus’s product specifications and test data can be used to show element-by-element non-infringement
3. Prior art fit: whether invalidity attacks are close (anticipation) or more attenuated (obviousness with multiple references)
4. Injunction posture: likelihood of irreparable harm findings based on likelihood of success and absence of adequate remedy
5. Settlement leverage: whether risk is concentrated in a single key patent versus a multi-patent estate

Key Takeaways

• The dispute is a Hatch-Waxman-style patent case filed in the District of New Jersey in 2024 under Case No. 3:24-cv-04330.
• Case value is primarily launch timing leverage through injunction and settlement dynamics.
• A complete patent-level infringement/invalidity analysis cannot be grounded in the input provided because the asserted patent numbers, claim scope, and docket events are not included.

FAQs

1. Is 3:24-cv-04330 a Paragraph IV ANDA litigation?
   The case posture is consistent with Hatch-Waxman Paragraph IV disputes, but the input does not include the Orange Book certification specifics.

2. What happens to Zydus’s FDA approval timeline during litigation?
   Patent litigation can delay effective launch through statutory stays and/or court orders, depending on the patents asserted and case milestones.

3. Does claim construction usually decide these cases?
   Claim construction often shifts leverage by narrowing infringement elements and redefining invalidity attack lines.

4. Can Zydus “design around” formulation or labeling patents?
   Yes in principle, but practical feasibility hinges on whether claims target core solid-state attributes, dosing regimens, or manufacturing steps.

5. How do settlements in these cases affect market entry dates?
   Settlements typically bind the parties to launch timing and can include covenants not to sue and/or licensing terms that reset expected entry dates.

References

1. Court docket identifier provided in prompt: Intra-Cellular Therapies, Inc. v. Zydus Pharmaceuticals (USA) Inc., 3:24-cv-04330 (D.N.J. 2024).